Glycopyrronium bromide - a new anticholinergic agent for the treatment of chronic obstructive pulmonary disease
Abstract
The article describes the principles of treatment of COPD according to the latest recommendations GOLD and historical overview of the use of anticholinergics. They include pathophysiological bases of their effect on muscarinic receptors M1 , M2 and M3.
The already known anticholinergic increasing new drug glycopyrronium bromide. Its efficacy has been demonstrated in comparison with placebo and tiotropium as a comparator , safety was evaluated in a study with placebo.
The fundamental glykopyrronia approval for the treatment of patients with COPD have become GLOW study 1 , 2 and 3 , the results of which are presented in this report. Efficiency and safety are fully comparable with tiotropium , still regarded as the gold standard.
Contrary to this drug glycopyrronium bromide has a faster onset of action - effect fully achieves tiotropium for 3 hours , glycopyrronium for 5-15 minutes. 28 9th 2012 has been a new drug glycopyrronium bromide centrally authorized in the European Union. For the treatment of patients Czech will be available during 2013.
The article also discussed the latest results of studies assessing treatment options for COPD dual agent composed of glykopyrronia and indacaterol. Results of the study SHINE , ILLUMINATE and SPARK, presented at the American Thoracic Society conference in Philadelphia in 2013 , are very promising.